

**BIOAGRI**

**Study title**  
A micronucleus study in mice for the product  
GLIFOS

**Data Requirements**

Instituto Brasileiro do Meio Ambiente  
e Recursos Naturais Renováveis - IBAMA  
Portaria Normativa nº139, of December 21<sup>th</sup>, 1994

**Study Completed on**  
November 18, 1996

**Performing Laboratory**

BioAgri - Biotecnologia Agrícola Ltda.  
Rod. SP 127 Km 24+62 m  
13412 - 000  
Piracicaba - São Paulo - Brasil

**Study Sponsor**

Cheminova Agro A/S  
Av. Interlagos, 7054 - Conj. 03  
Bairro Interlagos - São Paulo - SP  
CEP 04777-000

**BioAgri Report #**  
G.1.2 - 60/96





**This Page Reserved for Study Sponsor Requirements**

This document is not the property of EFSA and is provided for giving full effect to the right of public access to documents under EU law.

The document may be subject to rights such as intellectual property and copy rights of third parties.

Furthermore, this document may fall under a regulatory data protection regime.

Consequently, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document or its contents without the permission of the owner may therefore be prohibited and violate the rights of its owner.



### Study Compliance Statement

We the undersigned, declare that this study was performed under our supervision, according to the procedures herein described. This report represents an accurate and true recording of the results obtained and is scientifically valid.

An exact copy of raw data was provided to Cheminova Agro A/S with the final report. All original raw data were retained at BioAgri - Biotecnologia Agrícola Ltda..

[Redacted]  
Study Director  
[Redacted]

11-18-96  
mm/dd/yy

[Redacted]  
Director - BioAgri

11. 19. 96  
mm/dd/yy

Sponsor

mm/dd/yy




## Quality Assurance Documentation

This study have been reviewed by the Quality Assurance Unit of BioAgri. It has been found to accurately describe and/or identify the methods, practices and procedures employed the course of the study. Observations and results presents in this final report form a true and accurate representation of the raw data generated during the conduct of the study.

Report Number: G.1.2. - 60/96

Prepared by:



Biologist, CRB 14635-01

11-19-96  
mm/dd/yy

Approved by:



Quality Assurance Officer

11-19-96  
mm/dd/yy

This document is not the property of EFSA and is provided for internal use only. It may be subject to rights of public access to documents under a regulatory data protection regime. Consequently, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document may therefore be prohibited without the permission of the owner and violate the rights of its owner.

**INDEX**

	page
Study Compliance Statement .....	03
Quality Assurance Documentation .....	04
Index .....	05
Summary .....	06
General Information .....	07
I. Introduction .....	08
II. Material and Methods .....	08
III. Results .....	11
IV. Conclusion .....	11
V. References .....	12
VI. Tables	
Table 1. Effect of GLIFOS and cyclophosphamide on the number of micronuclei in male and female mice bone marrow erythrocytes .....	14
Table 2. Effect of GLIFOS and cyclophosphamide on the number of micronuclei in mice bone marrow erythrocytes .....	15
Table 3. Individual animal's erythrocyte differentiation .....	16
VII. Raw data .....	18
Appendix:	
Certificate of Analysis .....	25



## SUMMARY

A mouse bone marrow micronucleus assay was carried out in order to assess the mutagenic potential of the product GLIFOS by measuring its ability to induce chromosome breakage. The product was diluted in water and administered intraperitoneally twice with a 24 hour interval at levels of 68, 137 and 206 mg/kg corresponding to 75%, 50% and 25% of the LD<sub>50</sub> for mice, respectively. Determination of the LD<sub>50</sub> for the product as well as the negative and positive controls, used the two applications protocol with 24 hours interval. Negative control mice were treated with water and positive control mice with 25 mg/kg cyclophosphamide. Samplings were carried out 24 hours after the second application, when femurs were removed and smears of bone marrow cells prepared and stained. No increase in the number of polychromatic or normochromatric erythrocytes containing micronuclei was seen in animals treated with GLIFOS when compared to the vehicle control. A statistically significant increase in polychromatic and normochromatric erythrocytes containing micronuclei was observed in animals treated with cyclophosphamide. GLIFOS showed no evidence of mutagenic activity in this study.

## SUMMARY (Portuguese)

Foi conduzido o Teste do Micronúcleo para estudar possíveis efeitos mutagênicos do produto GLIFOS em camundongos. O produto foi administrado por via intraperitoneal em duas aplicações espaçadas de 24 horas nos níveis de 68; 137 e 206 mg/kg correspondendo a 75%, 50% e 25% da DL<sub>50</sub> para camundongos, respectivamente. A determinação da DL<sub>50</sub>, bem como os controles positivos e negativos foram também conduzidos com um esquema de duas aplicações espaçadas de 24 horas. O controle negativo utilizou o veículo de diluição e o positivo, 25 mg/kg de ciclofosfamida. As avaliações foram efetuadas 24 horas após a segunda aplicação, quando foram removidos os fêmurs dos animais e esfregaços da medula óssea foram preparados e corados. Não houve aumento no número de eritrócitos policromáticos ou normocromáticos contendo micronúcleos nos animais tratados com o GLIFOS em comparação com o controle negativo. Por outro lado, houve uma elevação estatisticamente significativa nessas variáveis em animais tratados com ciclofosfamida. Os resultados indicam que nas condições do teste o produto GLIFOS não apresentou atividade mutagênica em camundongos.

**BIOAGRI**

## **GENERAL INFORMATION**



## I. INTRODUCTION

The micronucleus test *in vivo* is a method devised primarily for screening chemicals for chromosome breaking effects (Schmid, 1975). The test substances are normally applied sub-acute to small mammals, and the effect is read in direct smears from bone marrow. Micronuclei arise mainly from chromosome fragments that are not incorporated into daughter nuclei at the time of cellular division, but they may also be generated from whole chromosomes that are not excluded from the telophase nucleus (Salamone & Heddle, 1983). The involvement of chromosomal aberrations, and thus of clastogens in carcinogenesis has been proposed by several authors (Cairns, 1981 ; Kinsella & Radman, 1978) because of the number of loci affected and structural rearrangements have greater consequences than do intragenic or point mutations.

The micronucleus test has been accepted as an indicator of chromosomal damage *in vivo* with about the same level of sensitivity as that of bone marrow metaphase analysis (Miller, 1973 ; Kliesch et al, 1982). This test is based on enumeration of micronuclei of mammalian bone marrow polychromatic erythrocytes (PCE). These cells are readily identifiable and have a relative short and defined life span, so that, any micronuclei they contain must have been generated as a result of recently induced chromosome damage. Other advantages of the test are the higher number of PCE and the consistent low rate of spontaneous micronucleated cells, in the region of three per thousand. The test also reacts positively to very low dosages of standard chromosome-breaking mutagens (Matter & Grauwiller, 1974 ; Von Ledebur & Schmid, 1973).

## II. MATERIAL AND METHODS

### 1. Test substance

The GLIFOS sample was received on 23/July/1996, in good conditions, as a brown liquid in a plastic container. The product was mixed with sterile distilled water at proportions of: 4.53, 9.13 and 13.7 mg/mL and mixed with a test tube mixer to a homogeneous suspension. Appropriate amounts of those suspensions were given to mice in order to have the dosages used for the test: 68, 137 and 206 mg/kg of animal. Those levels correspond to 75% , 50% and 25% of the LD<sub>50</sub> for mice.



## **2. Test Animal Management and Treatment.**

Swiss albino male and female mice (7-10 weeks) bred in the animal house of our laboratory, were used. The animals were maintained on wood shavings, in propylene rodent cages (five of the same sex per cage) with stainless steel mesh lids. They were fed a commercial pelleted diet (Labina, Purina) and water was available ad libitum. The group of animals for the test was selected within mice of about the same age, and a random selection was carried out for defining groups of animals for each treatment. After treatment, mice were randomized and housed in groups of ten per cage.

## **3. Determination of the LD<sub>50</sub>.**

The LD<sub>50</sub> was determined through the Thompson & Weil (1952) method using four levels of the product: 125, 250, 500 and 1000 mg/kg and 5 animals/level. The product was administered by two intraperitoneal injections with 24 hours interval. Total mortality number was considered at 10 days after treatment.

## **4. Test compound exposure.**

Three levels of the product were tested: 68, 137 and 206 mg/kg corresponding to 75%, 50% and 25% of the LD<sub>50</sub> for mice, with ten animals (five male and five female) per level. The animals were dosed twice with intraperitoneal injections in volumes of 0.4 to 0.5 mL/animal within a 24 hours interval, and sacrificed 24 hours after the second injection. Negative control with sterile distilled water and positive control with cyclophosphamide (5 mg/mL in physiological solution, corresponding to 25 mg/kg), were also applied with the two injections protocol. According to Mavournin *et al* (1990), with that protocol, two sequential cell populations are treated in each animal which then can be sampled simultaneously. MacGregor (1991) demonstrated that a high level steady state frequency of micronucleated cells was established during repeated dosing and concluded that the use of two to four injections of the product in the same animal, and only one sampling time improves the efficiency of the micronucleus test as compared to single dosing, multiple samplings protocol.



##### **5. Bone marrow preparation.**

The following protocol is an adaptation of the procedure described by Schmid (1975). Mice were killed by cervical dislocation 24 hours after the second dosing. From the freshly killed animal both femora were removed in total. The bones were then freed from muscle, the distal epiphyseal portion was torn off by gentle traction and the proximal end of the femur was shortened with scissors until a small opening of the marrow was visible. The bone marrow cells were gently flushed out with fetal calf serum (W.L. Imunoquímica). After centrifugation at 1,000 rev./min. for 5 min., the bone marrow cells were resuspended in fetal calf serum and smeared on glass slides which were air dried overnight. The following day, the smears were fixed in ethanol 70 % for 10 min. air dried and stained for 20 min. with Eosin-Methylene Blue solution (Giemsa) diluted to 1:30 with phosphate buffer (PBS), pH 6.8. The smears were then rinsed in PBS followed by rinsing in tapwater.

##### **6. Slide analysis.**

The slides were coded and observed with a 1,000X magnification objective in a Olympus microscope. The technicians were not allowed to know the corresponding coding in the slides. For each animal 1,000 polychromatic erythrocytes (PCEs) and 1,000 normochromatic erythrocytes (NCEs) were examined for the presence of micronuclei (MN). The relation PCEs/NCEs were determined in the first 1,000 PCEs or NCEs enumerated.

##### **7. Statistical analysis.**

Differences in the incidence per animal of MNPCEs and MNNECs per 1000 cells and the relation PCEs/NCEs were compared using the Mann-Whitney U test for k independent samples (Kruskal & Wallis, 1952 , cited by Coonover, 1980 ). All the tests were compared to the negative control. The criteria for a positive response was the detection of a reproducible and statistically significant ( $p = 0.05$ ) positive response for at least one dose level and the increase in the number of micronuclei to be at least twice the vehicle control. The test is considered valid only if the number of micronuclei in the vehicle control stays within the historic value of the laboratory.



### III. RESULTS

The LD<sub>50</sub> for the GLIFOS was 275 mg/kg. The micronucleus incidence data are presented on table 3. The data were analyzed with and without considering the sex of the animals (tables 1 and 2, respectively). In both cases the Mann-Whitney U test for k independent variables (Kruskal and Wallis, 1952) showed no effect of GLIFOS on micronucleus formation on mice bone marrow erythrocytes when compared to the negative control. There was no effect on the polychromatic and normochromatic erythrocytes ratio when the animals were treated with GLIFOS. A statistically significant increase in micronucleated polychromatic and normochromatic erythrocytes was observed in animals treated with cyclophosphamide.

### IV. CONCLUSION

Under the test conditions, the product GLIFOS did not have mutagenic activity in mice.

This document is not the property of EFSA and is provided for giving full effect to the right of public access to information under EU law.  
The document may be subject to rights such as intellectual property and copy rights of the owner.  
Furthermore, this document may fall under a regular data protection regime.  
Consequently, any publication, distribution, reproduction and/or publishing and any commercial use of this document or its contents without the permission and/or the rights of the owner may therefore be prohibited and violate the rights of its owner.

**V. REFERENCES**

1. Cairns, J. The origin of human cancers. *Nature* **289**: 353-357. 1981.
2. Conover, W.J. Practical nonparametric Statistics. ed. J. Wiley & Sons. New York. 2<sup>nd</sup> ed. 1980.
3. IBAMA - Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renováveis. Manual de testes para a avaliação da ecotoxicidade de agentes químicos. 1990.
4. Kinsella, A.R. & Radman, M. Tumor promoter induces sister chromatid exchange: Relevance to mechanisms of carcinogenesis. *Proc. Natl. Acad. Sci. U.S.A.* **75**:6149-6153. 1978.
5. Kliesch, U., Roupova, I & Adler, I.D. Induction of chromosome damage in mouse bone marrow by benzo(a)pyrene. *Mutation Res.*, **102**:265-273. 1982.
6. MacGregor, J.T. Micronucleus assay protocols. *Mutation Res.* **259**:123-125. 1991.
7. Mavourin, K.H. , Blakey, D.H. & Heddle, J.A.T. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene Tox Program. *Mutation Res.* **239**:29-80. 1990.
8. Miller, R.C. The micronucleus test as an *in vivo* cytogenetic method. *Environment Health Perspectives*, **6**:167-170. 1973.
9. Kruskal, W.H. & Wallis, W.A. Use of ranks on one-criterion variance analysis. *Journal of the American Statistical Association* **47**:583-621. Cited by Conover, 1980.

## Cont. Reference

10. Matter, B.E. & Grauwiller, J. Micronuclei in mouse bone marrow cells. A simple in vivo model for the evaluation of drug-induced chromosomal aberrations. *Mutation Res.* **23**:239-249. 1974.
11. Salamone, M.F. & Heddle, J.A. The bone marrow micronucleus assay: Rationale for a revised protocol. In: P.J. Serris, ed. *Chemicals Mutagens; Principles and Methods*. Plenum Press, **8**:111-143. 1983.
12. Schmid, W. The micronucleus test. *Mutation Research* **31**:9-15. 1975.
13. Thompson, W.R and Weil, C.S. *Biometrics*, **8**:51-54. 1952.
14. Von Ledebur, M. & Schmid, W. The micronucleus test. Methodological aspects. *Mutation Research* **19**:109-117. 1973.

This document is not the property of EFSA and is provided for information purposes only.  
The document may be subject to rights such as intellectual property and/or publishing rights of the owner.  
Consequently, any publication, distribution, reproduction and/or dissemination of this document or its contents without the express written permission of the owner may therefore be prohibited and violate the rights of its owner.

Table 1. Effect of GLIFOS and cyclophosphamide on the number of micronuclei in polychromatic and normochromic erythrocytes in male and female mice bone marrow. Each value is the mean of five animals.

Group	Sex	Micronuclei in 1000		Poly- chromatic eryth.	Normo- chrom. erythr.	Polychr./ normochr. ratio
		Polychr. erythr.	Normochr. erythr.			
Vehicle	1	0.80000	0.40000	550.20	903.800	0.73556
68 mg/kg	1	0.20000	0.00000	929.80	889.200	1.07919
137 mg/kg	1	0.60000	0.20000	814.40	934.600	0.91584
206 mg/kg	1	0.00000	0.00000	890.40	835.400	1.13639
Cyclophosph.	1	5.20000*	1.20000*	1002.40	957.000	1.04965
Vehicle	2	0.00000	0.00000	1000.00	803.667	1.24633
68 mg/kg	2	0.16667	0.16667	954.33	885.167	1.12713
137 mg/kg	2	0.16667	0.00000	925.33	741.167	1.44039
206 mg/kg	2	0.00000	0.00000	985.75	798.750	1.36099
Cyclophosph.	2	3.16667*	1.33333*	631.33	996.667	0.63940

\* Differ statistically from the vehicle control by the Mann-Whitney U test (Kruskal & Wallis, 1952) at \* for p = 0.05, and \*\* for p = 0.01.

Sex: 1= male; 2= female

Table 2. Effect of GLIFOS and cyclophosphamide on the number of micronuclei in polychromatic and normochromatic erythrocytes in mice bone marrow. Each value is the mean of ten animals.

Group	Micronuclei in 1000		Poly- chromatic eryth.	Normo chrom. eryth.	Polychr./ normochr. ratio
	Polychr. erythr.	Normochr. erythr.			
Vehicle	0.40000	0.20000	775.100	853.733	0.99095
68 mg/kg	0.18333	0.08333	942.067	887.183	1.10316
137 mg/kg	0.38333	0.10000	869.867	837.883	1.17812
206 mg/kg	0.00000	0.00000	938.075	817.075	1.24869
Cyclophosphamide	4.18333**	1.26667**	816.867	976.833	0.84453

\* Differ statistically from the vehicle control by the Mann-Whitney U test (Kruskal & Wallis, 1952) at \* for p = 0.05, and \*\* for p = 0.01.

This document is not the property of EFSA and is provided for giving full effect to the right of public access to documents under EU law. Consequently, any publication, distribution, reproduction and/or publishing and/or dissemination of this document or its contents may therefore be prohibited and violate the rights of the owner of this document such as intellectual property rights.

Table 3. Individual erythrocyte differentiation.

Dose	Sex	MNPE	MNNE	PE	NE	PE/NE ratio
0	1	4	2	445	1000	0.44500
0	1	0	0	1000	519	1.92678
0	1	0	0	273	1000	0.27300
0	1	0	0	337	1000	0.33700
0	1	0	0	696	1000	0.69600
1	1	0	0	1000	898	1.11359
1	1	0	0	863	1001	0.86214
1	1	1	0	739	1004	0.73606
1	1	0	0	1000	846	1.18203
1	1	0	0	1047	697	1.50215
2	1	0	0	1000	658	1.51976
2	1	0	0	653	1000	0.65300
2	1	1	0	849	1015	0.83645
2	1	0	0	870	1000	0.87000
2	1	2	1	700	1000	0.70000
3	1	0	0	834	1000	0.83400
3	1	0	0	1000	771	1.29702
3	1	0	0	617	1006	0.61332
3	1	0	0	1000	585	1.70940
3	1	0	0	1001	815	1.22822
4	1	1	1	1000	908	1.10132
4	1	0	0	1000	987	1.01317
4	1	1	0	898	1000	0.89800
4	1	24	5	1000	908	1.10132
4	1	0	0	1114	982	1.13442

SEX: 1= male, 2= female

DOSE: 0= negative control, 1= 68 mg/kg, 2= 137 mg/kg,  
3= 206 mg/kg of GLIFOS and 4= positive control (25 mg/kg  
of cyclophosphamide).

MNPE: number of micronuclei in 1,000 polychromatic  
erythrocytes.

MNNE: number of micronuclei in 1,000 normochromatic  
erythrocytes.

PE: Polychromatic erythrocytes.

NE: Normochromatic erythrocytes.

PE/NE ratio: Polychromatic/normochromatic erythrocytes ratio.



(cont.) Table 3. Individual erythrocyte differentiation.

Dose	Sex	MNPE	MNNE	PE	NE	PE/NE ratio
0	2	0	0	1000	811	1.23305
0	2	0	0	1000	839	1.19190
0	2	0	0	1000	761	1.31406
1	2	0	0	1000	826	1.21065
1	2	0	0	803	1001	0.80220
1	2	0	0	1000	580	1.72414
1	2	0	0	923	1000	0.92300
1	2	1	1	1000	981	1.01937
1	2	0	0	1000	923	1.08342
2	2	0	0	1000	374	2.67380
2	2	0	0	1000	805	1.24224
2	2	1	0	769	1000	0.76900
2	2	0	0	1000	684	1.46199
2	2	0	0	1000	584	1.71233
2	2	0	0	783	1000	0.78300
3	2	0	0	1000	458	2.18341
3	2	0	0	1016	873	1.16380
3	2	0	0	1029	849	1.21201
3	2	0	0	898	1015	0.88473
4	2	2	4	577	1051	0.54900
4	2	0	0	1000	929	1.07643
4	2	0	0	180	1000	0.18000
4	2	0	0	436	1000	0.43600
4	2	16	4	862	1000	0.862
4	2	1	0	733	1000	0.733

SEX: 1= male, 2= female

DOSE: 0= negative control, 1= 68 mg/kg, 2= 137 mg/kg,  
3= 206 mg/kg of GLIFOS and 4= positive control (25 mg/kg  
of cyclophosphamide).

MNPE: number of micronuclei in 1,000 polychromatic  
erythrocytes.

MNNE: number of micronuclei in 1,000 normochromatic  
erythrocytes.

PE: Polychromatic erythrocytes.

NE: Normochromatic erythrocytes.

PE/NE ratio: Polychromatic/normochromatic erythrocytes ratio.

Anexo II

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.  
TESTE DE MICRÓNÚCLEO EM CAMUNGOS G.1.2.

No. do Estudo: 060/96

Empresa: (CYANAMID) CHEMI NOVA AGRO

Produto: AC 303,757 - 36% SC

Solubilidade:

Estado Físico: Líquido

Solvente utilizado:  H<sub>2</sub>O       Óleo de milho

D1()    D2()    D3()    C-()    C+()

DOSE: 68 mg / Kg

APLICAÇÕES	QUANT./KG	DATA/HORÁRIO	MORTALIDADE
PRIMEIRA	68 mg	21/10 11:20	
SECUNDA	68 mg	22/10 11:20	

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	42	0,63		♂
	02	39	0,59		♂
	03	40	0,60		♂
	04	49	0,74		♂
	05	34	0,51		♂

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	38	0,57		♀
	02	31	0,47		♀
	03	32	0,48		♀
	04	37	0,47		♀
	05	30	0,45		♀
	06				
	07				

CONCENTRAÇÃO DA SOLUÇÃO: V = D x P / C:  $0,45 = 68 \times 0,03 / C$ :

C = 2,04

$0,45 = 4,53 \text{ mg} / \text{mL} \times 15 \text{ mL} = 68 \text{ mg} / 15 \text{ mL}$

DILUIÇÃO (PREPARO DA SOLUÇÃO) 9:5: p { produto -> 68 mg }

Solvente -> 15 ml

"This is an exact copy"

The original document

date 11-18-96

ASPECTO DA SOLUÇÃO: SOLUÇÃO

PREPARADO POR:

DATA: 23/10/96

Anexo II

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.  
TESTE DE MICRÓNÚCLEO EM CAMUNGOS G.1.2.

No. do Estudo: 060/96

Empresa: (CYANAMID) CHEMINOUA AGRO

Produto: AC 303, 757 - 36% S.C

Solubilidade:

Estado Físico: líquido

Solvente utilizado: () H<sub>2</sub>O      () Óleo de milho

D1() D2() D3() C-() C+

DOSE: 137 mg / Kg

APLICAÇÕES	QUANT./KG	DATA/HORÁRIO	MORTALIDADE
PRIMEIRA	137 mg	21/10 11:20	
SECUNDA	137 mg	22/10 11:20	

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	37	0,56		♂
	02	37	0,56		♂
	03	44	0,66		♂
	04	35	0,53		♂
	05	38	0,57		♂

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	28	0,42		♀
	02	28	0,42		♀
	03	31	0,47		♂
	04	32	0,48		♀
	05	30	0,45		♀
	06				
F = 0,015	07				

CONCENTRAÇÃO DA SOLUÇÃO: V = D x P / C:  $0,45 = 137 \times 0,03 / C$   
 $C = 4,11$

$0,45 = 913 \text{ mg} \cdot \text{mL}^{-1} \times 15 \text{ mL} = 137 \text{ mg} / 15 \text{ mL}$   
DILUIÇÃO (PREPARO DA SOLUÇÃO): q.s.p { produto -> 137 mg  
Solvente -> 16,86 mL }  
"This is an exact copy of  
The original document"

ASPECTO DA SOLUÇÃO: solúvel

PREPARADO POR:

DATA: 23 / 10 / 96

Anexo II

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.  
TESTE DE MICRONÚCLEO EM CAMUNGOS G.1.2.

No. do Estudo: 060/96

Empresa: (CYANAMID) CHEMINOVA AGRO

Produto: AC 303, 757 - 36% S.C

Solubilidade: Estado Físico: líquido

Solvente utilizado: () H<sub>2</sub>O      () Óleo de milho

D1() D2() D3() C-() C+()

DOSE: 206 mg / Kg

APLICAÇÕES	QUANT./KG	DATA/HORARIO	MORTALIDADE
PRIMEIRA	206 mg	21/10 11:20	
SECUNDA	206 mg	22/10 11:20	

No. DE ANIMAIS	No.	PESO (g)	VOL APLIC. (mL)	UNIDADES	SEXO
	01	43	0,65		♂
	02	43	0,63		♂
	03	44	0,66		♂
	04	46	0,63		♂
	05	37	0,56		♂

No. DE ANIMAIS	No.	PESO (g)	VOL APLIC. (mL)	UNIDADES	SEXO
	01	36	0,54		♀
	02	34	0,51		♀
	03	29	0,44		♂
	04	31	0,47		♀
	05	33	0,50		♀
	06	35	0,53		♂
F = 0,015	07	30	0,45		♀

CONCENTRAÇÃO DA SOLUÇÃO: V = D<sub>x</sub>P / C:  $0,45 = 206 \times 0,03 / C =$

C = 6,18

$0,45 = 13,73 \text{ mg} \cdot \text{mL} \times 15 \text{ mL} = 206 \text{ mg} / 15 \text{ mL}$

DILUIÇÃO (PREPARO DA SOLUÇÃO): q.s.p / produto → 206 mg

/ Solvente → 14,78 mL

"This is an exact copy  
The original document"

ASPECTO DA SOLUÇÃO: SÓL. SUL

date 11-18-96

PREPARADO POR:

DATA: 23/10/96

30 - 0,45 ♂

42 - 0,63 ♂

Pago 20 of 27 - Study - G1206096

Anexo II

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.  
TESTE DE MICRONÚCLEO EM CAMUNGOS G.1.2.

No. do Estudo: 060/96

Empresa: (CYANAMID) CHEMINOUA AGRO

Produto: AC 303, 757 - 36% S.C.

Solubilidade:

Estado Físico:

Líquido

Solvente utilizado: () H<sub>2</sub>O      () Óleo de milho

D1()   D2()   D3()   C-()   C+()

DOSE: 25 ml / Kg

APLICAÇÕES	QUANT/KG	DATA/HORÁRIO	MORTALIDADE
PRIMEIRA	<u>25 ml</u>	<u>21/10   14:30</u>	
SECUNDA	<u>25 ml</u>	<u>22/10   14:30</u>	

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	43	0,65		♂
	02	41	0,62		♂
	03	38	0,57		♂
	04	36	0,54		♂
	05	40	0,60		♂
No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	28	0,42		♀
	02	33	0,50		♀
	03	30	0,45		♀
	04	35	0,53		♂
	05	31	0,47		♀
	06				
F-0,015	07				

CONCENTRAÇÃO DA SOLUÇÃO: V = DxP / C: 25 ml de H<sub>2</sub>O para cada 30 gramos de peso corporal

DILUIÇÃO (PREPARO DA SOLUÇÃO):

"This is an exact copy of  
The original document"

date 11-10-96

ASPECTO DA SOLUÇÃO: sólida

B: \_\_\_\_\_

PREPARADO POR: \_\_\_\_\_

DATA: 23 / 10 / 96

Anexo II

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.  
TESTE DE MICRONÚCLEO EM CAMUNGOS G.1.2.

No. do Estudo: 060196

Empresa: (CYANAMID) CHEMINOUA AGRO

Produto: AC 303, 757 - 36% S.C

Solubilidade:

Estado Físico: líquido

Solvente utilizado: () H<sub>2</sub>O      () Óleo de milho

D1()    D2()    D3()    C-()    C+()

DOSE: 36,25 mg/Kg

APLICAÇÕES	QUANT./KG	DATA/HORÁRIO	MORTALIDADE
PRIMEIRA	36,25 mg	21/10/96 14:30	
SECUNDA	36,25 mg	22/10/96 14:30	

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	37	0,56		♂
	02	40	0,60		♂
	03	40	0,60		♂
	04	48	0,72		♂
	05	40	0,60		♂

No. DE ANIMAIS	No.	PESO (g)	VOL. APLIC. (mL)	UNIDADES	SEXO
	01	29	0,44		♀
	02	29	0,44		♀
	03	30	0,45		♀
	04	32	0,48		♀
	05	28	0,42		♀
	06				
	07				

CONCENTRAÇÃO DA SOLUÇÃO: V = D x P / C: 0,45 = 36,25 x 0,031C

C = 1,08

0,45 - 241 mg x 15 mL x = 36,25 mg / 15 mL 36,25 mg  
DILUIÇÃO (PREPARO DA SOLUÇÃO): de ciclorafomida foram solubles  
300g em 15 mL de solução salina 0,90, 45 mg de NaCl  
P/ cada 15 mL de H<sub>2</sub>O.

ASPECTO DA SOLUÇÃO:

"This is an exact copy of  
The original document"

PREPARADO POR:

By

date 11-18-96  
23/10/96

**BIOAGRI**

**BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.**  
**TESTE DE MICRONÚCLEO EM CAMUNGOS G.1.2.**

No. teste 060/96

Empresa CHÉMINOURA AGRO

Produto AC 303 757 - 36% S.C.

No. LAM.	DOSE	SEXO	MICRON POLICROM	MICRON NORMOCR	REL. POL/NORM	DATA
01	D1	0°	0	0	1000-898	06.11.96
02	D3	0°	0	0	834-1000	04.11.96
03	C-	0°	4	2	445-1000	08.11.96
04	D2	0°	0	0	1000-658	05.11.96
05	C+	♀	0	0	1000-814	05.11.96
06	D2	♀	0	0	1000-374	07.11.96
07	D3	♀	0	0	1000-458	06.11.96
08	C+	♀	2	4	577-1051	08.11.96
09	D1	0°	0	0	863-1001	06.11.96
10	C+	♀	0	0	1000-929	05.11.96
11	D1	♀	0	0	1000-826	05.11.96
12	C-	0°	0	0	1000-519	06.11.96
13	D3	0°	0	0	1000-771	05.11.96
14	D1	0°	1	0	739-1004	06.11.96
15	C+	♀	0	0	180-1000	05.11.96
16	C-	♀	0	0	1000-839	05.11.96
17	D2	0°	0	0	653-1000	06.11.96
18	C-	0°	0	0	273-1000	05.11.96
19	D1	♀	0	0	803-1001	04.11.96
20	C+	0°	1	1	1000-908	04.11.96
21	C-	♀	0	0		
22	D3	0°	0	0	617-1006	08.11.96
23	C+	♀	0	0	436-1000	08.11.96
24	C+	0°	0	0	1000-987	06.11.96
25	D2	♀	0	0	1000-805	05.11.96

"This is an exact copy of  
The original document"

date 11-18-96

By \_\_\_\_\_

Page 23 of 27 . Study . G1206096

**BIOAGRI**

**BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.**  
**TESTE DE MICRÓNÚCLEO EM CAMUNGOS G.1.2.**

No. teste 060/96

Empresa CHEMINOVA AGRO

Produto Ac. 303, 757 - 361. S.C

No. LAM.	DOSE	SEXO	MICRON POLICROM	MICRON NORMOCR	REL. POL/NORM	DATA
26	C-	♀	0	0	1000-761	07.11.96
27	C+	♂	1	0	898-1000	04.11.96
28	D2	♀	1	0	769-1000	05.11.96
29	D2	♂	1	0	849-1015	04.11.96
30	D3	♀	L			
31	D1	♀	0	0	1000-580	07.11.96
32	D3	♀	0	0	1016-873	07.11.96
33	D2	♂	0	0	870-1000	08.11.96
34	C+	♀	16	4	862-1000	04.11.96
35	D1	♀	0	0	923-1000	05.11.96
36	C+	♂	24	5	1000-908	07.11.96
37	D2	♂	2	1	700-1000	08.11.96
38	D1	♂	0	0	1000-846	06.11.96
39	D3	♀	0	0	1029-849	04.11.96
40	D1	♀	1	1	1000-981	04.11.96
41	D3	♀	0	0	898-1015	04.11.96
42	D1	♂	0	0	1047-697	05.11.96
43	C+	♀	1	0	733-1000	05.11.96
44	C-	♂	0	0	337-1000	08.11.96
45	D2	♀	0	0	1000-684	08.11.96
46	D3	♂	0	0	1000-585	06.11.96
47	C-	♂	0	0	696-1000	08.11.96
48	D2	♀	0	0	1000-584	06.11.96
49	C+	♂	0	0	1114-982	07.11.96
50	D3	♂	0	6	1001-815	05.11.96

PREPARADO POR:

DATA: 14/11/96

REVIDADO POR:

DATA: 13/11/96

"This is an exact copy of  
The original document"

By \_\_\_\_\_ date 11-11-96

**BIOAGRI**

CERTIFICATE OF ANALYSIS - CA 125/96

Subject: GLIFOS  
Common name: Glyphosate  
Product code (lab): 009/123  
Batch no.: 50928-01  
Date of analysis: 10/18/96  
Quantity: 960 ml

RESULTS OF ANALYSIS

We certify that analysis of the sample of the above product gave the following results:

Content of active ingredient: 360.0 g/l

Content of glyphosate was determined liquid chromatograph using a Hewlett Packard LC Model 1050 at the following conditions: UV detector, stainless steel column, ODS-HYPERSIL, 250mm x 4mm x 5 µm film thickness.

Piracicaba October 18, 1996.

"This is an exact copy of  
The original document"  
date 11-18-96

CRQ 04432306

By


Technical Director

Page 25 of 27 . Study - G1206096

BIOAGRI BIOTECNOLOGIA AGRÍCOLA

Rodovia Piracicaba/Rio Claro (SP-127) - Km. 24 - Tel.: 019/421-3731 - Fax: 019/421-1106 - CEP 13412-000 - Cx. Postal 573 Piracicaba SP

**BIOAGRI**




External Standard Report

File Name : C:\HPCHEM\2\DATA\GLIFOSAT\AM37.D  
ator : [REDACTED] Page Number : 1  
rument : HPLC 1050 Vial Number :  
le Name : GLIFOS FORMULADO Injection Number :  
Time Bar Code:  
ired on : 18 Oct 96 10:08 AM Sequence Line :  
rt Created on: 18 Oct 96 10:23 AM Instrument Method: GLIFOSAT.MTH  
Recalib on : 18 Oct 96 10:20 AM Analysis Method : GLIFOSAT.MTH  
iplier : 1 Sample Amount : 0  
TSTD Amount :  
  
2 in C:\HPCHEM\2\DATA\GLIFOSAT\AM37.D  
Tr Area Type Width Ref# ng/uL Name  
-----|-----|-----|-----|-----|  
.247 25609 BB 0.069 1 122.001 GLIFOSATO

"This is an exact copy of  
The original document"  
date 11-18-96

By [REDACTED]

**BIOACRI**



External Standard Report

File Name : C:\HPCHEM\2\DATA\GLIFOSAT\P38.D  
or :  
ment : HPLC 1050  
Name : PADRÃO  
me Bar Code:  
ed on : 18 Oct 96 10:00 AM  
Created on: 18 Oct 96 10:21 AM  
Recalib on : 18 Oct 96 10:20 AM  
lier : 1  
Instrument Method: GLIFOSAT.MTH  
Analysis Method : GLIFOSAT.MTH  
Sample Amount : 0  
ISTD Amount : 0

in C:\HPCHEM\2\DATA\GLIFOSAT\P38.D

Area	Type	Width	Ref#	ng/uL	Name
47	23677	58	0.076	1	112.800 GLIFOSATO

This document is not the primary document subject to rights such as intellectual property and copy rights of third parties.  
Consequently, any publication or distribution of this document may thereby infringe the rights of its owner.  
The document is provided for going to effect to the right of public access to documents under EU law.

"This is an exact copy of  
The original document"  
date 11-18-96

By

Page 27 of 27 - Study G1206096



Study title

The Salmonella typhimurium reverse mutation by GLIFOS

Data Requirements

Instituto Brasileiro do Meio Ambiente  
e Recursos Naturais Renováveis - IBAMA  
Portaria Normativa nº 139, of December 21<sup>th</sup>, 1994

Study Completed on

December 23, 1996

Performing Laboratory

BioAgri - Biotecnologia Agrícola Ltda.  
Rod. SP 127 Km 24+62m  
13412 - 000  
Piracicaba - São Paulo - Brasil

Study Sponsor

CHEMINOVA AGRO S.A.  
P.O. Box 9  
DK - 7620  
Lemvig - Denmark

BioAgri Report #

G.1.1 - 050/96





This Page Reserved for Study Sponsor Requirements

This document is not the property of EFSA and is provided for giving full effect to the right of public access to documents under EU law. Consequently, any publication, distribution, reproduction and/or publishing and any commercial exploitation and use of this document may therefore be prohibited and violate the rights of its owner. The document may fall under a regulatory data protection regime. Furthermore, this document, reproduction or its contents without the permission of the owner may be subject to rights such as intellectual property and copy rights of third parties. Of this document or its contents such as intellectual property such as intellectual property and copy rights of third parties.



### STUDY COMPLIANCE STATEMENT

We the undersigned, declare that this study was performed under our supervision, according to the procedures herein described. This report represents an accurate and true recording of the results obtained and is scientifically valid.

An exact copy of raw data was provided to CHEMINOVA AGRO S.A. with the final report. All original raw data were retained at BioAgri - Biotecnologia Agrícola Ltda..

[Redacted]  
Study Director

12/23/96  
mm/dd/yy

[Redacted]  
M.Sc., PhD.  
Director - BioAgri

12/23/96  
mm/dd/yy

[Redacted]  
Sponsor

mm/dd/yy

This document is not the property of EFSA and is provided full effe  
The document may be subject to rights subs  
Consequently, any publication, distribution or its contents without the permission and violate the rights of public access to documents under EU law.  
Furthermore, the document may be subject to rights subs  
of this document may therefore be prohibited and violate the rights of public access to documents under EU law.  
Under a regulatory data protection regime, a right of public access to documents under EU law.  
or any other publishing and any commercial exploitation by the owner.



### Quality Assurance Documentation

This study have been reviewed by the Quality Assurance Unit of BioAgri. It has been found to accurately describe and/or identify the methods, practices and procedures employed the course of the study. Observations and results presents in this final report form a true and accurate representation of the raw data generated during the conduct of the study.

Report Number: G.1.1. 050/96.

Prepared by:



12/23/96  
mm/dd/yy

Approved by:



12/23/96  
mm/dd/yy

Ph.D.  
Quality Assurance Officer

This document is not the property of EFSA. The document may be submitted to EFSA. Consequently, any publication, distribution or use of this document may be subject to copyright. Furthermore, this document may be used for internal purposes only and not for external distribution. The right of public access, property and copy rights of third parties, voluntary data protection regime, publishing and any commercial exploitation, without the permission of the owner, is prohibited and violate the rights of its owner.

**INDEX**

	page
Study Compliance Statement .....	03
Quality Assurance Documentation .....	04
Index .....	05
Summary .....	06
General Information .....	07
I. Introduction .....	08
Definitions .....	08
II. Material and Methods .....	08
III. Results .....	10
IV. Conclusion .....	10
V. References .....	11
VI. Statistic analysis through the program Salmonel.....	12
VII. Raw Data .....	28
VIII. Certificate of Analysis .....	31

This document is not the property of EPA and is provided for giving full effect to the right of public access to documents under EU law.  
The document may be subject to rights such as intellectual property and/or publishing and/or copy rights of third parties.  
Consequently, any publication, distribution, or its contents without the permission of the owner and/or violate the rights of its owner.

**TITLE OF THE ASSAY**

The Salmonella typhimurium reverse mutation assay by the chemical product GLIFOS

**SUMMARY**

A microbial assay was carried out with the product GLIFOS in order to study the possible mutagenic effect of that substance on the strains TA97a , TA98 , TA100 and TA1535 of Salmonella typhimurium in systems with and without metabolic activator (microsomal fraction of rat liver induced with AROCLOR 1254). The compound was tested with five concentrations, 0.001; 0.01; 0.1; 1 and 5 mg/plate of product. The positive controls, sodium azide and 2-aminofluorene produced the anticipated increases revertants, particularly after metabolic activation. The product GLIFOS did not produce an increase in reversion to histidine prototropy in the nonactivation and activation assays at any of the concentrations. These results indicate that, under the test conditions, the product GLIFOS did not exhibit genetic activity on the strains of Salmonella typhimurium used.

**SUMMARY (PORTUGUESE)**

Foi conduzido um teste microbiológico de mutagenicidade (Teste Ames) com o produto GLIFOS visando estudar possíveis efeitos genéticos nas cêpas TA97a , TA98 , TA100 e TA1535 de Salmonella typhimurium em sistemas com e sem ativador metabólico (fração microsomal de fígado de rato induzido com AROCLOR 1254). O produto foi testado em cinco concentrações, até o máximo de 0,001; 0,01; 0,1; 1 e 5 mg/placa do produto. Os controles positivos de azida de sódio e 2-aminofluoreno apresentaram os aumentos esperados nos números de revertentes, principalmente nos testes com ativador metabólico. O produto GLIFOS não produziu uma elevação no número de revertentes nos testes com e sem ativador metabólico em nenhuma das concentrações utilizadas. Esses resultados indicam que, nas condições do ensaio, o produto não apresentou atividade mutagênica na cêpas de Salmonella typhimurium.



## **GENERAL INFORMATION**

. Test Substance: GLIFOS

Chemical name: Sal de isopropilamina de N-(fosfonometil)-glicina

. Common name: Glyphosate

Declared Purity: 360.0 g/L

Analyzed Purity: 360.0 g/L

Sponsor: CHEMINOVA AGRO S.A.

.Study started on: 10/12/96

.Assay without metabolic activator started on: 12/20/96  
concluded on: 12/23/96

.Assay with metabolic activator      started on: 12/20/96  
concluded on: 12/23/96

Final report concluded on: 12/23/96

.Technical workers: Lab Technician

Total pages: 37



## I. INTRODUCTION

The Salmonella typhimurium (*his*) reversion system is a microbial assay which measures *his*- ----> *his*<sup>r</sup> reversion induced by chemicals which cause base change or frameshift mutations in the genome of this organism.

## DEFINITIONS

MEC = minimal effective concentration. It is the lowest concentration of a product (expressed as micrograms/plate or microliter/plate) that causes reverse mutations in any one of the S. typhimurium strains used.

## II. MATERIAL AND METHODS

### 1. Test substance

The test substance was GLIFOS. One gram of the product was added to 3 mL of sterile distilled water and mixed with a test tube mixer to a homogeneous solution. Appropriate dilutions were carried out in order to have the following levels of the substance per plate: 0.001; 0.01; 0.1; 1 and 5 mg/plate.

### 2. Organism

Strains TA98 , TA100 , TA97a and TA1535 of Salmonella typhimurium auxotroph to histidine (Ames et al., 1975) were used. Those strains were made histidine dependent (*his*<sup>r</sup>) through base pair substitutions (TA100 and TA 1535) or frameshift mutation (TA98 and TA97a) in the genome of the organism.

### **3. Principle of the method**

The test is designed to detect mutagenic substances that may cause his<sup>r</sup> reversion in the strains through base pair changes or frameshift mutation in the DNA of the organisms. This reverse mutations produce histidine independent strains that are capable of growing in a minimal medium without that amino-acid.

### **4. Reference substances**

Sodium azide (1.5 µg/plate) for TA100 and TA1535 in the assays with and without metabolic activator, and 2-aminofluorene (10 µg/plate) for TA98 and TA97a in the assays with metabolic activator were used as positive controls. Negative controls were included, with the solvent used in the test.

### **5. Direct plate incorporation method**

The sample was mixed with 0.1 mL of an overnight culture (8-12 hours old), that was added to 2 mL of top agar containing traces of histidine and biotin. This mixture was homogenized with a vortex for 2-3 seconds, and poured over the surface of a petri dish containing 30 ml of minimal agar medium containing 2 % of glucose (for strain TA97a, that level was reduced to 0.2 %). The tests with metabolic activation followed the Maron and Ames (1983) protocol with 20 µL/plate of the microsomal fraction of rat liver activated with AROCLOR 1254. This product was reconstituted from the freeze-dried product obtained from MolTox (Molecular Toxicology Inc., Annapolis, MD, U.S.A.). Triplicate plates were poured for each dose of the test substance. Negative controls containing the bacteria, S9 mix (when used) and the solvent, were prepared in order to establish the number of colonies that arise spontaneously for each of the tester strains. After incubation for 72 hours at 37°C, the number of colonies on the plate were counted.

### **6. Data management.**

Data were statistically analyzed with the statistical analysis program, Salmonel (Myers et. al., 1991). The substance is considered mutagenic when the following criteria are attended:

1. A statistically significant dose response curve is obtained at p= 0.05.
2. The number of revertants is at least twice the control for strains TA100 and TA97a , or at least three fold the control for strains TA98 and TA1535.



### III. RESULTS

The tests of histidine requirements, rfa mutation (permeability of the cell wall), mutation uvrB (UV sensitivity) and resistance to 25 µg/ml of Ampicillin (R-factor), confirmed that the tester strains had the genotypes required for the mutagenicity test. The values of spontaneous reversion of the tester strains to histidine independence were also within the historical values observed in our laboratory.

The positive control with sodium azide promoted a strong increase in the number of revertant of strain TA100 and TA1535 confirming the sensitivity of these strains to that mutagen. On the other hand the positive control with 2-AF (2-aminofluorene) only had mutagenic effect on strains TA97a and TA98 when the metabolic activator S9 was used. This product is not mutagenic in its original form and only its metabolized byproducts have genetic activity.

The results of the assay and the statistic analysis through the program Salmonel (appendix) indicate that the product GLIFOS did not have mutagenic activity within the levels tested.

### IV. CONCLUSION

Under the test conditions, the product GLIFOS did not have genetic activity in the strains of Salmonella typhimurium used in the assay.

This document is not the property of EFSA and is provided solely for the purpose of article 17(2) of Regulation (EC) No 1999/91. Consequently, any publication, distribution, reproduction or disclosure of this document may be subject to rights other than those granted under EU law.

## V. REFERENCES

1. Ames, B.N.; Mc Cann J. & Yamasaky E. 1975. Methods for detecting carcinogenics and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Res. 31:347-364. 1975.
2. Brusick, D.J. & Young, R.R. IERL-RTP. Procedures Manual: Level 1. Env. Ass. Biol. Tests. Washington, EPA, p 138 (EPA 600/8-81-024). 1981.
3. Environmental Monitoring Systems Laboratory, EPA. Data management Systems in genetic toxicology. Salmonel Assay Software, version 2.3 . 1989.
4. IBAMA - Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renováveis. Manual de testes para a avaliação da ecotoxicidade de agentes químicos. 1990.
5. Maron, D. & Ames, B. Compatibility of organic solvents with the Salmonella/microsome test. Mutation Research, 88:343-350. 1981.
6. Maron, D. & Ames, B. Revised methods for the Salmonella mutagenicity test. Mutation Research 113: 173-215. 1983.
7. Myers, L.E. , Adams, N., Kier, L , Rao, T.K., Shaw, B. & Willians, L. Microcomputer software for data management and statistical analysis of the Ames/Salmonella test. In: D. Krewisk (Ed.). Statistical Methods in Toxicological Research. Gordon and Breech, New York, pp 265-279. 1991.

This document is not the property of EFSA and cannot be reproduced without the permission of its owner.  
Consequently, any publication, distribution or communication of this document may therefore be subject to copyright protection and any use of this document may therefore be illegal unless authorised by the owner.



### Salmonella Assay

Test Sample Name: GLIFOS, without metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 1 Exp. Date: 12/27/96 Exp. No.: 050/96

Technician: [redacted]

Assay Type: Plate incorporation,

Strain: TA100 Activation S9: -

Data File Name: b:\model.sal

Code	Dose	--	counts	Mean	S.D.	Predicted
	mg/L					Linear
	0.00	153	152	169	9.54	143.14
	0.00	140	167	151	13.58	143.11
	0.01	130	159	142	14.57	142.85
	0.10	127	147	152	13.23	140.28
	1.00	75	121	97	23.01	114.58
	5.00	1	0	0	0.33	0.33
N	0.00	0	0	0		
P	0.00	300>	300>	300>		

S: Negative control for use in analysis (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.561

Estimate of the slope is = -28.561062 .

Standard error of the slope is ± 1.440000 .

90% confidence limits for the slope are <-31.127661, -25.994462>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000

Note: Smaller P-value means more positive dose response

**BIOAGRI**


Salmonella Assay

Record No.: 1  
No.: 050/96

Experiment Date: 12/27/96

Experiment

Test Sample Name: GLIFOS, without metabolic activator.  
Tester Strain: TA100



O = Observed; \* = Predicted.  
The predicted values are based on Linear model.



### Salmonella Assay

Test Sample Name: GLIFOS, without metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 2                    Exp. Date: 12/23/96                    Exp. No.: 050/96

Technician: [redacted]

Assay Type: Plate incorporation,

Strain: TA1535                   Activation S9: -

Data File Name: b:\model.sal

Code	Dose mg/L	--	counts	Mean	S.D.	Predicted Linear
	0.00	17	8	7	10.67	5.51
	0.00	8	10	7	8.33	1.53
	0.01	8	8	11	9.00	1.73
	0.10	9	13	7	9.67	3.06
	1.00	9	13	7	9.67	3.06
	5.00	0	0	0	0.00	0.00
P	0.00	300>	300>	300>		11.35

S: Negative control for use in analysis                    (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.947

ANOVA test is not significant. Other significant results  
should be viewed with caution.

An acceptable model is Linear with pval = 0.896

Estimate of the slope is = 0.413632 .

Standard error of the slope is = 1.915842 .

90% confidence limits for the slope are <-3.001091, 3.828354>.

P-value for the test of the positive dose response  
(slope at origin) is 0.416

Note: Smaller P-value means more positive dose response

**BIOAGRI**

Salmonella Assay

Record No.: 2


Experiment Date: 12/23/96

Experiment

No.: 050/96

Test Sample Name: GLIFOS, without metabolic activator.

Tester Strain: TA1535



O = Observed; \* = Predicted.  
The predicted values are based on Linear model.

## Salmonella Assay

Test Sample Name: GLIFOS, without metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 3      Exp. Date: 12/23/96      Exp. No.: 050/96

Technician: [REDACTED]

Assay Type: Plate incorporation,

Strain: TA98      Activation S9: -

Data File Name: b:\model.sal

Code Dose mg/L	--	counts	Mean	S.D.	Predicted Bernstein
0.00	24	34	21	26.33	6.81      20.13
0.00	17	20	16	17.67	2.08      20.12
0.01	16	25	17	19.33	4.93      20.00
0.10	14	20	21	18.33	3.79      18.78
1.00	6	5	9	6.67	2.08      6.65
5.00	1	1	4	2.00	1.73

S: Negative control for use in analysis      (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Bernstein with pval = 0.565

Berstein model used the first 5 doses

Estimate of the slope is = -13.477207 .

Standard error of the slope is = 2.247365 .

90% confidence limits for the slope are &lt;-17.482822, -9.471591&gt;.

P-value for the test of the positive dose response  
(slope at origin) is 1.000

Note: Smaller P-value means more positive dose response

**BIOACRI**


Salmonella Assay

Record No.: 3  
No.: 050/96

Experiment Date: 12/23/96

Experiment

Test Sample Name: GLIFOS, without metabolic activator.  
Tester Strain: TA98



O = Observed; \* = Predicted.  
The predicted values are based on Bernstein model.



### Salmonella Assay

Test Sample Name: GLIFOS, without metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 4      Exp. Date: 12/23/96      Exp. No.: 050/96

Technician: [redacted]

Assay Type: Plate incorporation,

Strain: TA97A      Activation S9: -

Data File Name: b:\model.sal

Code Dose mg/L	--	counts	Mean	S.D.	Predicted Linear
0.00	140	129	131	133.33	5.86
0.00	131	136	121	129.33	7.64
0.01	128	157	161	148.67	18.01
0.10	159	156	141	152.00	9.64
1.00	60	37	52	49.67	11.68
5.00	0	0	0	0.00	-316.38

S: Negative control for use in analysis      (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.094

Estimate of the slope is = -91.605420 .

Standard error of the slope is = 5.500154 .

90% confidence limits for the slope are <-101.408681, -81.802159>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000


Note: Smaller P-value means more positive dose response

## Salmonella Assay

Record No.: 4  
No.: 050/96

Experiment Date: 12/23/96

Experiment

Test Sample Name: GLIFOS, without metabolic activator.  
Tester Strain: TA97A

O = Observed; \* = Predicted.  
The predicted values are based on Linear model.



### Salmonella Assay

Test Sample Name: GLIFOS, with metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 5 Exp. Date: 12/23/96 Exp. No.: 050/96

Technician: [REDACTED]

Assay Type: Plate incorporation,

Strain: TA100 Activation S9: + RAT LIVER AROCLOR 4%

Data File Name: b:\model.sal

Code	Dose	--	counts	Mean	S.D.	Predicted
	mg/L					Linear
	0.00	161	168	151	160.00	8.54
	0.00	165	179	142	162.00	18.68
	0.01	160	169	151	160.00	9.00
	0.10	172	152	160	161.33	10.07
	1.00	110	133	121	121.33	11.50
	5.00	6	8	7	7.00	1.00
P	0.00	300>	300>	300>		6.98

S: Negative control for use in analysis (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.674

Estimate of the slope is = -30.472560 .

Standard error of the slope is = 0.657206 .

90% confidence limits for the slope are <-31.643939, -29.301180>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000


Note: Smaller P-value means more positive dose response

## Salmonella Assay

Record No.: 5  
No.: 050/96

Experiment Date: 12/23/96

Experiment

Test Sample Name: GLIFOS, with metabolic activator.  
Tester Strain: TA100

O = Observed; \* = Predicted.  
The predicted values are based on Linear model.



### Salmonella Assay

Test Sample Name: GLIFOS, with metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 6      Exp. Date: 12/23/96      Exp. No.: 050/96

Technician: [redacted]

Assay Type: Plate incorporation,

Strain: TA1535      Activation S9: + RAT LIVER AROCLOR 4%

Data File Name: b:\model.sal

Code Dose mg/L	--	counts	Mean	S.D.	Predicted Linear
0.00	16	16	14	15.33	1.15      10.26
0.00	12	4	11	9.00	4.36      10.26
0.01	14	19	10	14.33	4.51      10.24
0.10	7	14	9	10.00	3.61      10.09
1.00	6	5	8	6.33	1.53      8.53
5.00	1	1	3	1.67	1.15      1.61
P	0.00	300>	300>	300>	

S: Negative control for use in analysis      (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.134

Estimate of the slope is = -1.730787 .

Standard error of the slope is = 0.219199 .

90% confidence limits for the slope are <-2.121480, -1.340095>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000


Note: Smaller P-value means more positive dose response

## Salmonella Assay

Record No.: 6  
No.: 050/96

Experiment Date: 12/23/96

Experiment

Test Sample Name: GLIFOS, with metabolic activator.  
Tester Strain: TA1535

O = Observed; \* = Predicted.

The predicted values are based on Linear model.



### Salmonella Assay

Test Sample Name: GLIFOS, with metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 7      Exp. Date: 12/23/96

Exp. No.: 111

Technician: [redacted]

Assay Type: Plate incorporation,

Strain: TA98      Activation S9: + RAT LIVER AROCLOR 4%

Data File Name: b:\model.sal

Code Dose mg/L	--	counts	Mean	S.D.	Predicted Linear
0.00	26	23	20	23.00	3.00
0.00	14	13	17	14.67	2.08
0.01	9	14	21	14.67	6.03
0.10	9	10	20	13.00	6.08
1.00	7	5	11	7.67	3.06
5.00	0	2	0	0.67	1.15
P	0.01	300>	300>	300>	0.65

S: Negative control for use in analysis      (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.300

Estimate of the slope is = -2.570150 .

Standard error of the slope is = 0.333173 .

90% confidence limits for the slope are <-3.163985, -1.976315>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000

Note: Smaller P-value means more positive dose response

## Salmonella Assay

Record No.: 7


Experiment Date: 12/23/96

Experiment

No.: 111

Test Sample Name: GLIFOS, with metabolic activator.

Tester Strain: TA98



O = Observed; \* = Predicted.  
The predicted values are based on Linear model.



### Salmonella Assay

Test Sample Name: GLIFOS, with metabolic activator.

Source/Batch/Lot: 1

Solvent: DISTILLED WATER

Record No.: 8      Exp. Date: 12/23/96      Exp. No.: 050/96

Technician: [REDACTED]

Assay Type: Plate incorporation,

Strain: TA97A      Activation S9: + RAT LIVER AROCLOR 4%

Data File Name: b:\model.sal

Code	Dose mg/L	--	counts	Mean	S.D.	Predicted Linear
	0.00	133	157	143	144.33	12.06
	0.00	130	139	161	143.33	15.95
	0.01	149	152	143	148.00	4.58
	0.10	150	137	151	146.00	7.81
	1.00	117	140	120	125.67	12.50
	5.00	0	11	15	8.67	7.77
P	0.01	300>	300>	300>		8.69

S: Negative control for use in analysis      (solvent control)

N: Negative control not used in analysis

P: Positive control not used in analysis

P-value for ANOVA test of dose response is 0.000

An acceptable model is Linear with pval = 0.990

Estimate of the slope is = -27.782229 .

Standard error of the slope is = 1.558277 .

90% confidence limits for the slope are <-30.559642, -25.004815>.

P-value for the test of the positive dose response  
(slope at origin) is 1.000


Note: Smaller P-value means more positive dose response

## Salmonella Assay

Record No.: 8  
No.: 050/96

Experiment Date: 12/23/96

Experiment

Test Sample Name: GLIFOS, with metabolic activator.  
Tester Strain: TA97A

O = Observed; \* = Predicted.  
The predicted values are based on Linear model.

MOLTOX™ POST MITOCHONDRIAL SUPERNATANT (S-9)  
PRODUCTION & QUALITY CONTROL CERTIFICATE

LOT NO.: 0668      SPECIES: Rat      PREPARATION DATE: 21 May 1996  
 CT NO.: 11-01L      STRAIN: Sprague Dawley      EXPIRATION DATE: 21 May 1998  
 VOLUME: 2.1ml      SEX: Male      BUFFER: 0.154M KCl  
 TISSUE: Liver      INDUCING AGENT(s): Aroclor 1254  
 REFERENCE: Maron, D & Ames, B. Mutat. Res. 113:173, 1983      Monsanto Lot No. KL615 - 500mg/kg  
 USE: Reconstitute with 2.1ml sterile purified water.

CHEMISTRY:

- PROTEIN

36.8 mg/ml

Assayed according to the method of Lowry et al., JBC 193:265, 1951 using bovine serum albumin as the standard.

"This is an exact copy of  
The original document"

- ALKOXYRESORUFIN-O-DEALKYLASE ACTIVITIES

Activity	P450	Fold - Induction
EROD	IA1, IA2	238.9
PROD	2B1, 3B2	51.9
BROD	3A, 2B	27.0

By [REDACTED] date 12-12-96 and  
Assays for esterases and benzylxyresorufin-O-dealkylases (PROD, BROD) were conducted using a modification of the methods of Burke et al., Biochem Pharm 34:3337, 1985. Fold-inductions calculated as the ratio of the sample vs. uninduced control specific activities (SA). Control SA's (pmoles/min/mg protein) were 7.71, 3.75 & 50.3 for EROD, PROD & BROD, respectively

ASSAY:

- STERILITY TEST

Samples of S-9 were assayed for the presence of contaminating microflora by plating 1.0ml volumes on Trypticase Soy and Minimal Glucose (Vogel-Bonner E, supplemented with 0.05mM L-histidine and D-biotin) media. Triplicate plates were read after 48 or 72h incubation at 37C. No evidence of contamination was observed.

- PROMUTAGEN ACTIVATION

No. His+ Revertants	
EtBr/	CPA/
A98	TA1535
974.6	1267

The ability of the sample to activate ethidium bromide (EtBr) and cyclophosphamide (CPA) to intermediates mutagenic to TA98 and TA1535, respectively, was determined according to Lesca, et al., Mutation Res 129:299, 1984. Data were expressed as revertants per ug EtBr or per mg CPA.

Dilutions of the sample S9, ranging from 0.2 - 10% in S9 mix, were tested for their ability to activate benzo(a)pyrene (BP) and 2-aminoanthracene (2-AA) to intermediates mutagenic to TA100. Assays were conducted using duplicate plates as described by Maron & Ames (Mutat. Res. 113:173, 1983.).

Promutagen	0	1	2	10	20	50
BP (5ug)	85.5	261.5	519.5	615.5	804	820.5
2-AA (2.5ug)	100	516.5	1212.5	1208.5	1224	1177.5

ECULAR TOXICOLOGY, INC.  
33 Bralter St  
Baltimore, MD 21401  
268 7232

BIOAGRI - BIOTECNOLOGIA AGRÍCOLA LTDA.

## Laboratório de Mutagenicidade

### TESTE AMES (G.1.1.)

Test Code: 50196

Product Code: 071, 004 Lot#: 50928 - QP

Product: Gluco

Sponsor: cheninova

Aspect of Product: ( X ) Liquid      ( ) Solid

Density:

Solvent: (  ) water (  ) DMSO (  ) Others

Lot 59: 0668

Technician:

Date: 3/12/96

Checked by:

Date: 11/10/04

Date: 11/23 / 16

"This is an exact copy of  
The original document"

By

date 12-23-96

Test Code: 50/96

Treatment: (I) without activador metabolic  
(II) with activador metabolic

Start of test: 20/12/96 Final of test: 23/12/96

Strain: 100

Control I	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent	0.025	40	0.001	140	167	151
	0.25	40	0.01	180	159	142
	2.5	40	0.1	127	147	152
	25	40	1	75	21	97
	250	20	5	1	0	0
				153	153	169
	0.015 mg	100	1.5 ug	<i>"This is an exact copy of the original document"</i>		

Strain: 100 By \_\_\_\_\_ date 23-23-96

Control II	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent	0.025	40	0.001	165	129	142
	0.25	40	0.01	160	169	151
	2.5	40	0.1	172	152	160
	25	40	1	110	133	121
	250	20	5	b	8	07
				161	163	151
	0.015 mg	100	1.5 ug	2300	2300	2300

Test Code: 750/96

Treatment: (  ) without activador metabólico  
(  ) with activador metabólico

Start of test: 20/12/96 Final of test: 23/12/96

Strain: 1535

Control	stock solution (mg/mL)	Volume/plate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent negative	0.025	40	0.001	8	10	7
	0.25	40	0.01	8	8	11
	2.5	40	0.1	9	13	07
	25	40	1	4	5	6
	250	20	5	0	0	0
				17	8	07
positive	0.015 mg	100	1.5 ug	"This is an exact copy of The original document"		

Strain: 1535

By

date 12-23-96

Control	stock solution (mg/mL)	Volume/plate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent negative	0.025	40	0.001	12	4	11
	0.25	40	0.01	14	19	10
	2.5	40	0.1	7	14	09
	25	40	1	6	5	08
	250	20	5	1	1	03
				16	16	14
positive	0.015 mg	100	1.5 ug	>300	>300	>300

Test Code: 50/96

Treatment: (I) without activador metabolic  
(II) with activador metabolic

Start of test: 20/12/96 Final of test: 23/12/96

Strain: 98

Control I	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
	0.025	40	0.001	17	20	16
	0.25	40	0.01	16	25	17
	2.5	40	0.1	14	20	21
	25	40	1	6	5	0
	250	20	5	1	4	04
solvent negative						
				34	34	21
positive	0.015 mg	100	1.5 $\mu$ g			

"This is an exact copy of  
The original document"

Strain: 98

Control II	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
	0.025	40	0.001	14	13	17
	0.25	40	0.01	9	14	21
	2.5	40	0.1	9	10	20
	25	40	1	7	5	11
	250	20	5	0	2	0
solvent negative				26	23	20
				2300	2300	2300
positive	0.015 mg (2.1)	100	1.5 $\mu$ g 0.015 $\mu$ g			

Test Code: 150/96

Treatment: (I) without activador metabolic  
(II) with activador metabolic

Start of test: 20/11/96 Final of test: 23/12/96

Strain: 979

Control I	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent negative positive	0.025	40	0.001	131	136	121
	0.25	40	0.01	128	150	161
	2.5	40	0.1	159	156	141
	25	40	1	60	37	52
	250	20	5	0	0	0
				140	129	131
0.015 mg 1.5 ug 0.015 mg				"This is an exact copy of The original document"		

Strain: 979 By: \_\_\_\_\_ date 12.12.96

Control I	stock solution (mg/mL)	Volume/pl ate (uL)	conc./plate (mg)	Plate 1	Plate 2	Plate3
solvent negative positive	0.025	40	0.001	130	139	161
	0.25	40	0.01	149	152	143
	2.5	40	0.1	150	137	151
	25	40	1	117	190	120
	250	20	5	0	11	15
				133	152	143
0.015 mg 1.5 ug 0.015 mg				>300	>300	>300

Page 33 of 37 - Study G.11-05096



PHONE NO. : +55 11 5231517

Sep. 13 1996

CHEMINOVA Agro A/S  
P. O. Box 9  
DK-7620 Lemvig  
Denmark

Phone (+45) 97 63 41 00  
Fax (+45) 97 63 45 55  
Telex 66513 CHEMV DK  
A/S reg.no. 177.122

## ANEXO I

### 1. Produto Técnico

Marca Comercial : Glyphosate Technical  
Ingrediente Ativo : GLIFOSATO (ISO)  
Concentração : 96% glifosato  
Tipo de Formulação : produto técnico  
Lote : 229-JAK-142-6

Identificação da amostra: AC 303,757 87.2% wet cake

### 2. Produto Formulado

Marca Comercial : Glifos  
Sinônimas : CHE 3607, CHE 3690  
Ingrediente Ativo : GLIFOSATO  
Concentração : Glifosato como sal de isopropilamina  
480 g/litro (ou 360 g/litro como  
Glifosato puro).  
Tipo de formulação : solução aquosa  
Lote : 50928-01

Identificação da amostra: AC 303,757 36% SC

"This is an exact copy of  
The original document"

B)

- date 12-23-96

Page 34 of 37 - Study G.11-050/96

**BIOAGRI**

CERTIFICATE OF ANALYSIS - CA 125/96

Subject: GLIFOS  
Common name: Glyphosate  
Product code (lab): 009/123  
Batch no.: 50928-01  
Date of analysis: 10/18/96  
Quantity: 960 ml

RESULTS OF ANALYSIS

We certify that analysis of the sample of the above product gave the following results:

Content of active ingredient: 360.0 g/l

Content of glyphosate was determined liquid chromatograph using a Hewlett Packard 10C Model 1050 at the following conditions: UV detector, stainless steel column, DGS-HYPERSEIL, 250mm x 4mm x 5  $\mu$ m film thickness.

Piracicaba October 18, 1996.

"This is an exact copy of  
The original document"

By

date 12-23-96

CR 04432306

Technical Director

**BIOANALY**

GLIFOSATO 1.247

=====  
External Standard Report  
=====

File Name : C:\HPCHEM\2\DATA\GLIFOSAT\AM37.D  
for : [REDACTED] Page Number : 1  
Instrument : HPLC 105C Vial Number :  
Sample Name : GLIFOS FORMULADO Injection Number :  
Sample Bar Code:  
Recorded on : 18 Oct 96 10:08 AM Sequence Line :  
Created on: 18 Oct 96 10:23 AM Instrument Method: GLIFOSAT.MTH  
Recalibrated on : 18 Oct 96 10:26 AM Analysis Method : GLIFOSAT.MTH  
Dilution : 1 Sample Amount : 0  
ISTD Amount :  
[REDACTED]

2 in C:\HPCHEM\2\DATA\GLIFOSAT\AM37.D  
in Area Type Width Ref# ng/uL Name  
-----|---|---|---|---|-----|-----|  
247 25609.66 0.069 1 122.001 GLIFOSATO  
=====

"This is an exact copy of  
The original document"

By

date 12-23-96

**EIDAGRI**

GLIFOSATO 1.247

External Standard Report

File Name : C:\HPCHEM\2\DATA\GLIFOSAT\P38.D  
Dr : [REDACTED] Page Number : 1  
ument : HPLC 1050 Vial Number :  
Name : PADRÃO Injection Number :  
me Bar Code:  
ed on : 18 Oct 96 10:00 AM Instrument Method: GLIFOSAT.MTH  
Created on: 18 Oct 96 10:21 AM Analysis Method : GLIFOSAT.MTH  
e calib on : 18 Oct 96 10:20 AM Sample Amount : 0  
lier : 1 ISTD Amount :  
  
in C:\HPCHEM\2\DATA\GLIFOSAT\P38.D  
m Area Type Width Ref# ng/uL Name  
47 23677 ED 0.076 1 112.800 GLIFOSATO

"This is an exact copy of  
The original document"

By [REDACTED]

date 12-23-96